Citations

Clear

368 citation(s) found for "Wolf, DM".

Capsule Retention in Crohn’s Disease: A Meta-analysis
Pasha, Shabana F., Pennazio, Marco , Rondonotti, Emanuele , Wolf, Douglas C. , Buras, Matthew , Albert, Jörg , Cohen, Stanley A. , Cotter, José , D’Haens, Geert , Eliakim, Rami, Leighton, Jonathan A. , Buras, Matthew R , Rondonotti, Emanuele , Rubin, David T.

Mayo Clinic

Inflammatory Bowel Diseases | May 3, 2019 | Volume: 26 | Issue: 1 | Pages: 33-42

10.1093/ibd/izz083 | PMID 31050736 Get It

This systematic review showed lower capsule retention rates in suspected and established Crohn’s disease than older literature. Retention rates were further reduced after patency capsule and cross-sectional imaging. Retention rates were also lower in pediatric compared with adult Crohn’s disease.
Catalyzing Research to Optimize Cancer Survivors’ Participation in Work and Life Roles
Newman, Robin , Radomski, Mary Vining , Pergolotti, Mackenzi , Voelbel, Gerald T. , Moor, Janet S. de , Nitkin, Ralph, Daniels, Elvan, Braveman, Brent , Walker, Rae , Campbell, Scott E., Lawlor, Mary , King, Allison A. , Ness, Kirsten K. , Lyons, Kathleen Doyle , King, Allison A , Alfano, Catherine M. , Wolf, Timothy , Sleight, Alix G. , Bryant, Ashley Leak , Williams, Grant R. , Winters‐Stone, Kerri M. , Cheville, Andrea , Campbell, Scott E., Srivastava, Piyush, Ness, Kirsten K

Mayo Clinic

OTJR: Occupational Therapy Journal of Research | May 3, 2019 | Volume: 39 | Issue: 4 | Pages: 189-196

10.1177/1539449219844749 | PMID 31046601 Get It

Participation refers to a state of health in which a person is able to fully engage in roles and life situations. Adults living with and beyond cancer often report persistent participation restrictions that affect their productivity and quality of life. The American Occupational Therapy Foundation convened a group of scientists from seven different disciplines in a Planning Grant Collective (PGC) to stimulate research to identify scalable ways to preserve and optimize participation among cancer survivors. Participants identified challenges, prioritized solutions, and generated novel research questions that move beyond symptom and impairment mitigation as outcomes to identify interventions that improve participation in roles and life situations. This article summarizes the PGC discussion and recommendations regarding three challenges: (a) the dynamic and multi-faceted nature of participation, (b) a need to integrate the concept of participation within the culture of oncology, and (c) identification of priority areas in which new lines of research regarding participation would be most impactful.
Comparing the incidence of ventricular arrhythmias during epicardial ablation in swine versus canine models
Caluori, Guido , Wojtaszczyk, Adam , Yasin, Omar , Pešl, Martin , Wolf, Jiří , Bělašková, Silvie , Crha, Michal, Sugrue, Alan , Vaidya, Vaibhav R. , Naksuk, Niyada , Killu, Ammar M. , Padmanabhan, Deepak , Asirvatham, Samuel J. , Stárek, Zdeněk , DeSimone, Christopher V , Killu, Ammar M , Stárek, Zdeněk , Asirvatham, Samuel J , DeSimone, Christopher V.

Mayo Clinic

Pacing and Clinical Electrophysiology | April 16, 2019 | Volume: 42 | Issue: 7 | Pages: 862-867

10.1111/pace.13698 | PMID 30989679 Get It

Abstract Background Choosing the appropriate animal model for development of novel technologies requires an understanding of anatomy and physiology of these different models. There are little data about the characteristics of different animal models for the study of technologies used for epicardial ablation. We aimed to compare the incidence of ventricular arrhythmias during epicardial radiofrequency ablation between swine and canine models using novel epicardial ablation catheters. Methods We conducted a retrospective study using data obtained from epicardial ablation experiments performed on swine ( Sus Scrofa ) and canine ( Canis familiaris ) models. We compared the incidence of ventricular arrhythmias during ablation between swine and canine using multivariate regression analysis. Six swine and six canine animals underwent successful epicardial radiofrequency ablation. A total of 103 ablation applications were recorded. Results Ventricular arrhythmias requiring cardioversion occurred in 13.11% of radiofrequency ablation applications in swine and 9.75% in canine (relative risk: 117.6%, 95% confidence interval [CI]: 83.97‐164.69, animal‐based odds ratio [OR]: .55, 95% CI: .23‐61.33; P = .184). When adjusting for application position, duration of ablation and power, the odds of developing potentially lethal ventricular arrhythmia in swine increased significantly compared to canine (OR: 3.60, 95% CI: 1.35‐9.55; P = .010). Conclusions The swine myocardium is more susceptible to developing ventricular arrhythmias compared to canine model during epicardial ablation. This issue should be carefully considered in future studies.
Protein activation mapping and exploratory predictive markers for pCR in triple-negative breast cancer patients treated with neratinib in the I-SPY 2 TRIAL.
Wulfkuhle, Julia , Deng, Jianghong , Hirst, Gillian L. , Liu, Minetta C. , Park, John W., Berry, Donald A. , Veer, Laura van’t, Petricoin, Emanuel F. , Investigators, I-SPY 2 TRIAL, Hirst, Gillian L , Yau, Christina , Wolf, Denise M. , Gallagher, Rosa I. , Swigart, Lamorna Brown , Esserman, Laura J. , Investigators, I-SPY 2 TRIAL

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 1085-1085

10.1200/jco.2015.33.15_suppl.1085 Get It

P499 Efficacy and safety of 2 or 3 vedolizumab intravenous infusions as induction therapy for ulcerative colitis and Crohn’s disease: results from VISIBLE 1 and 2
Sandborn, William J. , Wolf, Douglas C. , Yao, Xinyi , Kisfalvi, Krisztina, Vermeire, Séverine , Loftus, Edward V. , Danese, Silvio , Chen, Jingjing , Vermeire, Séverine

Mayo Clinic

Journal of Crohn's and Colitis | January 25, 2019 | Volume: 13 | Issue: Supplement_1 | Pages: S361-S362

10.1093/ecco-jcc/jjy222.623 Get It

Burnout among palliative care clinicians in the United States: Results of a national survey.
Bull, Janet , Wolf, Steven , Samsa, Gregory P., Ast, Katherine , Abernethy, Amy Pickar, Kamal, Arif H. , Swetz, Keith M. , Shanafelt, Tait D.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: e20530-e20530

10.1200/jco.2014.32.15_suppl.e20530 Get It

Should Researchers Offer Results to Family Members of Cancer Biobank Participants? A Mixed-Methods Study of Proband and Family Preferences
Gordon, Deborah R., Breitkopf, Carmen Radecki , Robinson, Marguerite , Petersen, Wesley O., Egginton, Jason S. , Chaffee, Kari G. , Petersen, Gloria M. , Koenig, Barbara A. , Rabe, Kari G. , Wolf, Susan M.

Mayo Clinic

AJOB Empirical Bioethics | December 31, 2018 | Volume: 10 | Issue: 1 | Pages: 1-22

10.1080/23294515.2018.1546241 | PMID 30596322 Get It

Prospective front-line management patterns in the Real World Metastatic Renal Cell Cancer (MaRCC) Registry.
Wolf, Steven , Costello, Brian A. , Vaishampayan, Ulka N. , Kyriakopoulos, Christos E. , Hammers, Hans J. , Tsao, Che‐Kai, Pal, Sumanta K. , Hussain, Arif , Borham, Azah, George, Daniel J. , Vaishampayan, Ulka , Harrison, Michael R. , Bhavsar, Nrupen Anjan , Stadler, Walter M. , Appleman, Leonard J. , Jim, Heather

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: e16097-e16097

10.1200/jco.2016.34.15_suppl.e16097 Get It

Deferred systemic therapy (DST) in the prospective metastatic renal cell cancer (MaRCC) registry.
Wolf, Steven , Costello, Brian A. , Vaishampayan, Ulka N. , Kyriakopoulos, Christos E. , Hammers, Hans J. , Tsao, Che‐Kai, Pal, Sumanta K. , Hussain, Arif , Borham, Azah, George, Daniel J. , Vaishampayan, Ulka , Harrison, Michael R. , Bhavsar, Nrupen Anjan , Stadler, Walter M. , Appleman, Leonard J. , Jim, Heather

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: e16084-e16084

10.1200/jco.2016.34.15_suppl.e16084 Get It

A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women over age 50 with BI-RADS 3, 4, or 5 Assessment
Henderson, Meredith C. , Silver, Michael, Tran, Quynh Hoa, Letsios, Elias, Mulpuri, Rao, Reese, David E., Lourenço, Ana P. , Anderson, Karen S. , Alpers, Josie , Costantini, Carrie , Rohatgi, Nitin, Ali, Haythem , Baker, Karen, Northfelt, Donald W. , Ghosh, Karthik, Grobmyer, Stephen R. , Polen, Winnie, Wolf, Judith K., Ali, Haythem , Tran, Quynh, Letsios, Elias E., LaBaer, Joshua , Baker, Karen

Mayo Clinic

Clinical Cancer Research | September 5, 2018 | Volume: 25 | Issue: 1 | Pages: 142-149

10.1158/1078-0432.ccr-18-0843 | PMID 30185421 Get It

Abstract Purpose: With improvements in breast cancer imaging, there has been a corresponding increase in false-positives and avoidable biopsies. There is a need to better differentiate when a breast biopsy is warranted and determine appropriate follow-up. This study describes the design and clinical performance of a combinatorial proteomic biomarker assay (CPBA), Videssa Breast, in women over age 50 years. Experimental Design: A BI-RADS 3, 4, or 5 assessment was required for clinical trial enrollment. Serum was collected prior to breast biopsy and subjects were followed for 6–12 months and clinically relevant outcomes were recorded. Samples were split into training (70%) and validation (30%) cohorts with an approximate 1:4 case:control ratio in both arms. Results: A CPBA that combines biomarker data with patient clinical data was developed using a training cohort (469 women, cancer incidence: 18.5%), resulting in 94% sensitivity and 97% negative predictive value (NPV). Independent validation of the final algorithm in 194 subjects (breast cancer incidence: 19.6%) demonstrated a sensitivity of 95% and a NPV of 97%. When combined with previously published data for women under age 50, Videssa Breast achieves a comprehensive 93% sensitivity and 98% NPV in a population of women ages 25–75. Had Videssa Breast results been incorporated into the clinical workflow, approximately 45% of biopsies might have been avoided. Conclusions: Videssa Breast combines serum biomarkers with clinical patient characteristics to provide clinicians with additional information for patients with indeterminate breast imaging results, potentially reducing false-positive breast biopsies.